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Concerns that variola virusesmight be used as bioweapons have renewed the interest in developing new and safer smallpox vaccines.
Variola virus genomes are now widely available, allowing computational characterization of the entire T-cell epitome and the use of
such information to develop safe and yet effective vaccines. To this end, we identified 124 proteins shared between various species of
pathogenic orthopoxviruses including variola minor and major, monkeypox, cowpox, and vaccinia viruses, and we targeted them
for T-cell epitope prediction. We recognized 8,106, and 8,483 unique class I and class II MHC-restricted T-cell epitopes that are
shared by all mentioned orthopoxviruses. Subsequently, we developed an immunological resource, EPIPOX, upon the predicted T-
cell epitome. EPIPOX is freely available online and it has been designed to facilitate reverse vaccinology.Thus, EPIPOX includes key
epitope-focused protein annotations: time point expression, presence of leader and transmembrane signals, and known location
on outer membrane structures of the infective viruses. These features can be used to select specific T-cell epitopes suitable for
experimental validation restricted by single MHC alleles, as combinations thereof, or by MHC supertypes.
1. Introduction
Smallpox was a devastating contagious disease that ravaged
humankind for millennia, wiping out entire civilizations [1].
The disease was caused by two types of variola virus (VARV),
major and minor, which differed greatly in their average
mortality rates: 30% versus 1%, respectively. VARVmajor was
themost prevalent form [2, 3]. Systematic vaccination against
smallpox began in the early 19th century but the disease
lingered until the World Health Organization (WHO) initi-
ated worldwide vaccination campaigns in 1967. The last case
was reported in Somalia in 1977 and in May 1980 the WHO
declared that smallpox had been eradicated, ceasing vaccina-
tion [1, 2]. Eradication was facilitated because there are no
animal reservoirs for the virus, as it only infects humans [4].
VARV belongs to the Orthopox genus of the Poxviridae
family, consisting of large double-stranded DNA viruses that
replicate in the cytoplasm of infected cells [5, 6]. Poxviruses
are large and complex with ∼250 genes and a multistage life
cycle, producing different infective forms including intracel-
lular mature virions (IMV) and extracellular enveloped virus
(EEV) [5, 6]. Humans can be infected by several poxviruses;
the closest to VARV that are also pathogenic to humans are
vaccinia (VACV), cowpox (CPXV), andmonkeypox (MPXV)
viruses [7, 8]. The primary reservoir of MPXV is rodents
[9], while CPXV has the broadest animal reservoir range
of all poxvirus, including cats, dogs, elephants, and rodents
[10]. Historically, VAVC has been considered to emerge after
repeated passages from an ancestral CPXV [11]. However,
phylogenetic studies question that view and there are some
speculations that VACV could be a horsepox virus (HPXV)
[12]; yet both, the host and origin of VACV, remain unknown
[13]. VACV and CPXV infections in humans are gener-
ally mild and self-limiting and can induce cross-protective
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immunity [14]. The observation that CPXV sufferers did
not get smallpox led Edward Jenner in 1798 to introduce a
method of vaccination through scarifications with Variolae
Vaccinae, Latin, for CPXV [15]. Immunization with CPXV
was eventually displaced by VACV vaccine, which was used
subsequently for global smallpox vaccination [12].
As smallpox was eradicated and vaccination ceased, the
global population has become increasingly susceptible to
both smallpox and zoonosis by orthopoxviruses [8, 9]. People
under 30 have no immunity against these viruses and VACV-
induced immunity is waning in those that were vaccinated
[16]. Despite recommendations by the WHO, stockpiles of
smallpox virus had never been destroyed and there are con-
cerns that unregistered stocks could be used as a weapon of
bioterrorism [17]. Several featuresmake smallpox amajor ter-
rorist threat. It replicates easily, is aerosolizable, and is highly
contagious before, during, and after disease onset. Moreover,
smallpox is lethal and disfiguring and has already been used
as a biological weapon in North America during the French
and Indian Wars [18]. Thus, there is renewed interest in the
development of vaccines against smallpox, particularly safer
ones, since immunization with VACV can result in serious
adverse events and it is considered risky in immunocompro-
mised or immune-suppressed individuals [19].
Immune protection against orthopoxviruses requires
both B and T cells [20] but the relevance of T cells is
paramount. CD8 T cells are required to eliminate infected
cells, while help by CD4 T cells is essential to elicit effective
humoral responses [21]. Thus, people with dysfunctional
humoral responses (e.g., agammaglobulinemia) can be vac-
cinated with VACV, while those with loss of T cells cannot as
they can suffer severe disease [22]. T-cell immune responses
are triggered by the recognition of foreign peptides bound
to cell surface-expressed major histocompatibility complex
(MHC) molecules, also known as human leukocyte antigens,
HLA, in humans. CD4 T cells recognize peptides presented
byMHCclass II (MHC II)moleculeswhileCD8T cells recog-
nize peptides presented by MHC class I (MHC I) molecules.
Advances in both immunology and genomic analysis
offer new possibilities for eliciting immune protection with-
out the requirement for live-virus vaccination and atten-
dant complications. The identification of HLA class I and
class II restricted T-cell epitopes (CD8 and CD4 T-cell
epitopes, resp.) from poxviruses may allow us to develop
safe and yet immunogenic peptide-based vaccines. Here,
we describe the identification of protein antigens that are
shared between several pathogenic orthopoxviruses, includ-
ing VARV,MPXV, CPXV, and VACV, and T-cell epitopes that
are identical in all selected proteins. This information was
used to create a freely accessible web resource, EPIPOX: URL
http://imed.med.ucm.es/epipox/, intended to facilitate the
design of epitope-based vaccines against orthopoxviruses.
2. Materials and Methods
2.1. Orthopoxvirus Sequences and Experimentally Defined T-
Cell Epitopes. In this study, we used the entire proteomes
of 8 orthopoxviruses: VARV major, strain Bangladesh-1975,
Table 1: Orthopoxviruses used in this study.
Virus Strain ACC Genes
VARV major Bangladesh-1975 L22579 189
VARV major India-1967 NC 00161 197
VARV minor Garcia-1966 Y16780 206
MPXV Zaire-96-I-16 NC 003310 191
CPXV Brighton Red AF482758 218
VACV Copenhagen M35027 262
VACV Tian Tan AF095689 243
VACV Ankara∗ U94848 157
∗Modified strain that has lost the ability to replicate; VARV: variola virus;
MPXV: monkeypox virus; CPXV: cowpox virus; VACV: vaccinia virus.
GenBank Accession: GB: L22579; VARV major, strain India-
1967, GB: NC 00161; Variola major minor, strain Garcia-1966,
GB: Y16780; Monkeypox virus, strain Zaire-96-I-16, GB:
NC 003310; Cowpox virus strain, strain Brighton Red, GB:
AF482758, Vaccinia virus, strain Copenhagen, GB: M35027;
Vaccinia virus, strain Tian Tan, GB: AF095689; Vaccinia
virus, strain Ankara, GB: U94848. The proteomes were
obtained from the various translation features of the relevant
GenBank genomic records using BIOPERL [23] (Table 1).
We also used experimentally defined poxvirus-specific
HLA I and HLA II-restricted T-cell epitopes that were
retrieved from the IEDB [24] and EPIMHC [25] databases.
We only considered unique T-cell epitope sequences with
a size of 9 amino acids that were reported to be identified
in humans infected with orthopoxviruses or who were
vaccinated. We provide a list of experimentally defined T-cell
epitopes as supplementary material in Additional File S1 in
Supplementary Material available online at http://dx.doi.org/
10.1155/2015/738020.
2.2. Protein Sequence Analyses and Annotations. We took
VARV major, strain Bangladesh-1975, as the reference for
subsequent sequence analyses. We identified proteins with
leader signals using SIGNALP [26] and transmembrane
regions using TMHMM[27].We identified protein orthologs
using BLAST [27]. Briefly, we first BLAST the reference
proteins against formatted databases of each of the remaining
orthopoxvirus proteomes. We performed BLAST searches
with default settings and considered only the description of
the first hit and the corresponding alignment. Subsequently,
we selected those protein searches that gave hits in each of the
proteomes with identities greater than 60% and identified the
corresponding orthologs.We used BIOPERL to parse BLAST
hits [23].
Information on the temporal expression of VACV genes
was kindly provided by Dr. Lefkowitz from the Poxvirus
Bioinformatics Resource Center [28]. The information con-
sisted on annotations identifying those genes that are
expressed early (E), intermediate (I), and late (L) during
the life cycle of VACV. This information is provided as
supplementary material in Additional File S2. In addition,
we identified, from the data provided by Dr. Lefkowitz, gene
products associatedwith the outermembranes of VACV IMV
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Figure 1: EPIPOX database structure. EPIPOX is a relational database consisting of three main tables: peptides, predictions, and proteins.
Table names are boxed with double lines. For each table, we show their fields and boxed with single lines the fields that work as table keys.
For fields taking discrete nominal values, we show them between square brackets.
and EEV infective forms, as well as those proteins that are
part of the VACV virion or CORE. This information is also
included as supplementary material in Additional File S2.
Protein annotations obtained for VACV were transferred to
protein orthologs.
2.3. Prediction of T-Cell Epitopes. We predicted MHC I and
MHC II peptide binding to anticipate potential CD8 and
CD4 T-cell epitopes, respectively. Specifically, we predicted
peptide-MHC binding from VARV Bangladesh proteins that
are shared between all selected orthopoxviruses using 32
HLA I- and 33HLA II-allele specific position-specific scoring
matrices (PSSMs) [29–31]. For a given protein, we considered
the top 2% and 4% of scoring peptides to constitute HLA I-
andHLA II-binding peptides, respectively.We only predicted
binding for peptides of nine residues; most HLA I-restricted
peptides are 9 residues in length and while HLA II-restricted
peptides vary in length (9–22 amino acids) they have a
core of 9 residues that anchor the peptide in the binding
groove of HLA II molecules [30, 32]. We also used N-
gram language models to identify whether peptides can be
generated from the source antigen by proteasomal cleavage
[33]. This information is only relevant to HLA I-binding
peptides, sincemost peptides presented byMHC I are derived
from antigens degraded by the proteasome [34].
2.4. Database Building and Web Server Implementation.
Predicted T-cell epitopes and obtained protein annotations
were incorporated into a POSTGRES relational database.
The database consists of 3 tables (peptides, predictions, and
proteins) that are linked through unique keys (Figure 1).
Briefly, table predictions contains peptide sequences and their
MHC restriction elements; table peptides includes the peptide
molecular weight, its protein accession number, and whether
the peptide is cleaved by the proteasome; and table pro-
teins contains gene product information including temporal
expression (E: early, I: intermediate, and L:late), location
in the virus (IMV, EEV, and CORE), and the existence of
leader and transmembrane regions. We also developed a
web front end or GUI to allow ready access to EPIPOX.
Behind the interface is a Python script that handles database
queries through underlying SQL. The EPIPOX resource is
implemented on an Apache Web server under the Mac OSX
operating system.
3. Results and Discussion
3.1. Epitope-Vaccine Design against Orthopoxviruses. T-cell
adaptive immunity is required for clearance of poxviruses
during infection and/or vaccination and can also contribute
to protective immunity from subsequent exposures [35, 36].
Moreover, peptides corresponding to VACV-specific CD8
T-cell epitopes can confer protection to mice subjected to
lethal VACV challenges [37]. Fueled by the need to develop
safer smallpox vaccines, such knowledge has led to the
recent identification of many VACV-specific T-cell epitopes
[37, 38]. These T-cell epitopes are deposited haphazardly in
various specialized databases, including IEDB [24], EPIMHC
[25], TEPIDAS [39], and AntiJen [40]. Of relevance for
epitope-vaccine design, CD8 T-cells target primarily early
and nonstructural gene products [41, 42]. CD4 T cells target
late and the most abundant genes products (IMV and EEV
membrane proteins and CORE proteins), as do antibodies
[42, 43]. While some of the identified VAVC-specific T-
cell epitopes are conserved in VARV a rational approach
to identifying all potential T-cell epitopes eliciting cross-
protective immunity is still required.
3.2. SharedOrthopoxvirus Proteins for Cross-Protective Immu-
nity. Nearly all orthopoxviruses can protect against chal-
lenge with another orthopoxvirus [14]. This exquisite cross-
protective immunity is likely a result of direct antigenic simi-
larity between poxviruses.Therefore, prior to defining poten-
tial T-cell epitopes we identified shared antigens between
pathogenic orthopoxviruses. Identification of shared anti-
gens is also relevant to reducing the experimental bur-
den associated with T-cell identification. Human pathogen
orthopoxviruses have large genomes encompassing over 180
open reading frames (ORF) with the exception of VACV
Ankara strain, which has only 157 genes and lacks the
ability to replicate [44] (Table 1). Using VARV major, strain
Bangladesh-1975, as a reference, we identified 124 ORFs that
are shared between 8 different complete genomes from sev-
eral orthopoxviruses, including VARVminor, CPXV, MPXV,
and several VACV strains (Additional File S3). Despite the
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Table 2: Orthopoxvirus proteins contributing to cross-protective immunity.
VACC: GI|ORF VARV: GI|ORF MPXV: GI|ORF CPXV: GI|ORF LOC1/EXP2/TM3/LD4
335424|L1R 438991|M1R 17974993|M1R 20153082|V099 IMV/late/yes/no
335455|D8L 439016|F8L 17975018|E8L 20153106|V119 IMV/late/yes/no
335500|A27L 439052|A31L 17975052|A29L 20153143|V156 IMV/late/no/no
335508|A33R 439057|A36R 17975058|A35R 20153149|V162 EEV/early/yes/no
335549|B5R 439084|B6R 17975080|B6R 20153177|V190 EEV/#/yes/yes
335438|H3L 439004|I3L 17975006|H3L 20153094|V107 IMV/late/yes/no
335477|A10L 439032|A11L 17975034|A11L 20153122|V135 CORE/#/no/no
335341|C7L 438926|D11L 17974926|D10L 20153015|V028 U/early/no/no
Table shows GenBank identification numbers (GI) and open reading frame names (ORF) for VACC (strain Copenhagen), VARV (strain Bangladesh-1975),
MPXV (strain Zaire-96-I-16), and CPXV (strain Brighton Red). 1LOC: location, 2EXP: temporal expression, 3TM: transmembrane, and 4LD: leader signal.
NS: nonstructural gene. #: information not available. U: unknown. List of proteins was obtained from [45]. Annotations 1, 2, 3, and 4 obtained as indicated
elsewhere in Section 2.
criterion for selection being 60% identity, all 124 selected
proteins have an average identity ≥ 85% as shown in Addi-
tional File S3. These proteins are prime candidates to induce
cross-protective immunity although they need to be targeted
by the immune system. Interestingly, within the selected
proteins there are 8 known immunogens that conferred>60%
protection to VACV in animal models (Table 2) [45]. Six
of these immunogens are IMV or EEV proteins carrying
transmembrane regions and/or are being late gene products.
Interestingly, among the selected 124 proteins we found 26
additional proteins with transmembrane regions that could
also be prime vaccine subunits candidates (Table 3). Some
of these proteins also have leader signal sequences (Table 3).
Viral proteins with leader sequences follow the cell secretory
pathway and are thus also important targets to consider for
vaccine design [46, 47].
3.3. T-Cell Epitome from Pathogenic Orthopoxvirus Proteins.
We targeted the shared orthopoxvirus proteins for T-cell
epitopes prediction using 32 and 33 HLA I- and HLA II-
specific profile matrices (details in Material and Methods).
The alleles targeted for peptide binding prediction are shown
in Additional File S4. We selected these alleles because there
are experimental peptide-binding data for them, which is
required to make accurate peptide-MHC binding predictors
[48]. Incidentally, these HLA alleles are frequently expressed
in the general population and targeting them for epitope pre-
diction permits the development of epitope-based vaccines
covering the entire population. These HLA allelic variants
can have overlapping peptide-binding repertoires and can
be clustered accordingly in supertypes [49, 50]. Selecting
promiscuous peptide-binders to multiple HLA molecules
facilitates the development of vaccines with a minimum
number of peptides [49–51].
We predicted a total of 18726 HLA I-restricted and 32722
HLA II-restricted orthopoxvirus specific T-cell epitopes, all
being identical between all orthopoxviruses considered in
this study. In Additional File S4 we provide numbers of T-
cell epitopes predicted by each HLA-specific profile used
in this study. We predicted more CD4 than CD8 T-cell
epitopes because we used a more permissive peptide-binding
threshold forMHC II molecules (4% of top scoring peptides)
than for MHC I molecules (2% of top scoring peptides)
since peptide-binding prediction to MHC II molecules is
considerably less accurate than to MHC I molecules [46].
Interestingly, we identified only 8106 uniqueHLA I-restricted
T-cell epitope sequences and a few more (8483) unique HLA
II-restricted T-cell epitope sequences. Therefore, there is a
considerable overlap between the peptide binding repertoires
of HLA molecules, which is larger for HLA II molecules
than for HLA I molecules. HLA I-restricted peptides bound
on average to 2.3 distinct HLA I molecules, while HLA II-
restricted peptides bound on average to 3.8 distinct HLA
II molecules. This is due to the fact that peptide-binding
to MHC II molecules is more degenerate than to MHC I
molecules [29, 30]. In Additional File S5, we provide all
distinct predicted peptides with the HLA molecules that
they were predicted to bind. Interestingly, there is also some
overlap between HLA I- and HLA II-restricted peptides. In
particular, we find that there are 2452 peptides that are pre-
dicted to be restricted by both HLA I and HLA II molecules.
Thus, in total the predicted T-cell epitome consisted of just
14137 unique sequences among all predicted T-cell epitopes.
We compared the predicted T-cell epitome with exper-
imentally defined poxvirus-specific HLA-restricted T-cell
epitopes deposited in the IEDB [24] and EPIMHC [25].
We retrieved 170 HLA I and 9 HLA II-restricted T-cell
epitopes meeting our criteria (see Additional File S1) but
we only considered for comparison 85 HLA I- and 8 HLA
II-restricted T-cell epitopes that we identified here to be
conserved in all orthopoxviruses considered in this study. Of
those, 72 HLA I- and 6HLA II-restricted T-cell epitopes were
found within our predicted T-cell epitome. Moreover, we
predicted the experimentally verified restriction element in
> 80%. The experimentally determined and shared epitopes
that were not predicted (a minority) either are restricted by
noncovered alleles or were simply not predicted. In Table 4,
we summarize the data showing the verified and predicted
HLA restriction elements. In sum, we readily predicted most
of the experimentally verified T-cell epitopes. Considering
that on average 10% of predicted T-cell epitopes can be
experimentally verified [52], we shall expect that there are
many more valid T-cell epitopes remaining to be validated
within the T-cell epitome predicted in this study.
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Table 3: Shared orthopoxvirus proteins with transmembrane and/or leader sequences.
VARV GI|ORF MPXV GI|ORF CPXV GI|ORF VACV GI|ORF IDEN1 (%) TM2 LEAD3 EXP4 LOCATION5
GI:439084|B6R GI:17975080|B6R GI:20153177|V190 GI:335549|B5R 93.1 Yes Yes L EEV membrane∗
GI:439016|F8L GI:17975018|E8L GI:20153106|V119 GI:335455|D8L 94.7 Yes No L IMV membrane∗
GI:438990|H9R GI:17974992|G10R GI:20153081|V094 GI:335423|G9R 98.1 Yes No L U
GI:438919|D4R GI:17974919|D3R GI:20153007|V020 GI:335333|C11R 88.8 Yes Yes U U
GI:439085|B7R GI:17975081|B7R GI:20153178|V191 GI:335550|B6R 93.1 Yes No U U
GI:439035|A14L GI:17975037|A14L GI:20153125|V138 GI:335483|A13L 88.6 Yes No L IMV membrane
GI:438946|C8L GI:17974949|C10L GI:20153036|V049 GI:335366|F4L 97.6 Yes No E U
GI:438977|K5L GI:17974979|I5L GI:20153068|V081 GI:335409|I5L 94.9 Yes No L IMV membrane
GI:438967|E8R GI:17974969|F7R GI:20153058|V071 GI:335395|E8R 97.4 Yes No L U
GI:439004|I3L GI:17975006|H3L GI:20153094|V107 GI:335438|H3L 95.8 Yes No L IMV membrane∗
GI:439014|F6R GI:17975016|E6R GI:20153104|V117 GI:335453|D6R 99.0 Yes No L U
GI:439003|I2R GI:17975005|H2R GI:20153093|V106 GI:335437|H2R 99.2 Yes No L U
GI:439056|A35L GI:17975057|A34L GI:20153148|V161 GI:335506|A32L 98.1 Yes No L U
GI:439000|L5L GI:17975002|L5L GI:20153090|V103 GI:335433|J5L 98.1 Yes No L U
GI:439058|A37R GI:17975059|A36R GI:20153150|V163 GI:335509|A34R 98.1 Yes No L EEV membrane
GI:438991|M1R GI:17974993|M1R GI:20153082|V095 GI:335424|L1R 99.2 Yes No L IMV membrane∗
GI:439057|A36R GI:17975058|A35R GI:20153149|V162 GI:335508|A33R 93.0 Yes No E EEV membrane∗
GI:438951|C13L GI:17974954|C15L GI:20153041|V054 GI:335373|F9L 97.5 Yes No L U
GI:439038|A17L GI:17975040|A17L GI:20153129|V142 GI:335486|A16L 97.0 Yes No L U
GI:438974|K2L GI:17974976|I2L GI:20153065|V078 GI:335405|I2L 99.3 Yes No L U
GI:439008|I7R GI:17975010|H7R GI:20153098|V111 GI:335442|H7R 95.2 Yes No L U
GI:438982|H3L GI:17974984|G2L GI:20153073|V086 GI:335414|G3L 95.8 Yes No L U
GI:439042|A22L GI:17975044|A21L GI:20153134|V147 GI:335490|A21L 96.9 Yes No U U
GI:439059|A38R GI:17975061|A38R GI:20153152|V165 GI:335512|A36R 92.3 Yes No E, L EEV membrane
GI:439031|A10L GI:17975033|A10L GI:20153121|V134 GI:335476|A9L 89.0 Yes Yes E, L U
GI:439033|A12R GI:17975035|A12R GI:20153123|V136 GI:335481|A11R 98.5 Yes No L U
GI:439036|A15L GI:17975038|A15L GI:20153126|V139 GI:335484|A14L 97.8 Yes No L IMV membrane
GI:439067|A46R GI:17975066|A43R GI:20153159|V172 GI:335522|A43R 92.3 Yes Yes U U
GI:439039|A18L GI:17975041|A18L GI:20153130|V143 GI:335487|A17L 98.0 Yes No L IMV membrane
GI:439077|J7R GI:17975076|B2R GI:20153172|V185 GI:335539|A56R 82.1 Yes Yes E, L EEV membrane
GI:439062|A41L GI:17975063|A40L GI:20153155|V168 GI:335516|A38L 94.7 Yes Yes U U
Table shows GenBank identification numbers (GI) and open reading frame names (ORF) for VARV: strain Bangladesh-1975, MPXV: strain Zaire-96-I-16,
CPXV: strain Brighton Red, and VACV: strain Copenhagen. 1IDEN: average identity between the selected proteins. 2TM: transmembrane. 3LEAD: leader
signal. 4EXP: temporal expression (E: early, I: intermediate, and L: late). 5LOCATION: location. ∗Proteins known to induce protective immunity (see Table 2).
Annotations were obtained as indicated elsewhere in Section 2. U: information not found.
3.4. EPIPOX Database and Web Server. We developed a
relational database based upon the predicted T-cell epit-
ome and a web-based resource to facilitate online access
and to query the database. We named this resource
EPIPOX and made it available for free public use (URL:
http://imed.med.ucm.es/epipox/). EPIPOX is a de facto anal-
ysis pipeline of viral T-cell epitomes. The content of the
EPIPOX database is organized in three tables (peptides,
predictions, and proteins) (Figure 1).The table predictions con-
tains all predicted T-cell epitopes, consisting of 18726 HLA I-
and 32722 HLA II-restricted peptides, each identified by its
sequence and restriction element. Peptide sequences in this
table are not unique as each peptide can bind to numerous
HLA I molecules. Peptide sequences are, however, unique
in the table peptides. This table contains 14137 sequences
comprising the whole predicted epitome regardless of the
restriction elements. Antigen annotations in EPIPOX are
found within the table proteins (Figure 1). We only included
annotations that are relevant to epitope vaccine design,
such as temporal expression of gene products and location
in relevant structures of the virus such as the EEV and
IVM membranes and CORE. Early expressed proteins and
highly expressed proteins are generally thought to be more
immunogenic, particularly with regard to CD8 T cells [53,
54]. On the other hand, highly abundant late proteins that
are located in membrane structures of the poxvirus appear to
be the main focus of the antibody and CD4 T-cell response
[42, 43]. In the table proteins, we also provide annotations on
whether the proteins have transmembrane region or leader
signal sequence, as proteins with these features often interact
with host cells and are important targets for subunit vaccine
design [46, 47].
The EPIPOX web interface (Figure 2) allows querying of
the database combining any annotation field in the database,
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Figure 2: EPIPOX input page. The input page of EPIPOX is divided in two main sections for intuitive use. In the first part (SEARCH), users
select HLA molecules and proteins to retrieve T-cell epitopes (multiple selection is allowed) while in the second part the user can limit the
search output according to various criteria. These criteria include temporal expression of gene products (E: early; I: intermediate; L: late),
location of proteins in relevant structures of the virus (CORE, IMV, and EEV), and the presence of leader and transmembrane regions. In
addition, users can select only those peptides with a relative score above some selectable value. HLA-specific profiles used to score T-cell
epitopes can reach a maximum score, which is used to set the relative score in percentage of each peptide. For HLA I-restricted epitopes,
users can also restrict the search to those epitopes potentially generated by the proteasome.
as described above. For intuitive use, the interface is divided
in two main sections. In the first section (SEARCH), users
select proteins and restriction elements for epitope retrieval.
In this section, EPIPOX also provides the option to query
the database for promiscuous T-cell epitopes binding to three
HLA I supertypes (A2, A3, and B7). The alleles belonging
to these supertypes are present in 88% of the population
regardless of their ethnic groups. Selecting promiscuous pep-
tides restricted by these 3 supertypes facilitates maximizing
the population coverage of vaccines with minimum numbers
of peptides [49, 50, 55]. In the second section (LIMIT),
users can select annotation criteria to restrict the results.
As an example, in Figure 3, we show the page resulting
from a sample query consisting of promiscuous peptides
from CORE binding to the A2 supertype. From the EPIPOX
output, users can also access additional information available
from the Virus Pathogen Resource database (Figure 3) [56].
EPIPOX is related somewhat to certain existing
databases. On the one hand, it shares features with generic
epitope databases such as EPIMHC [25], AntiJen [40], and
IEDB [24] and on the other hand it shares features with
poxvirus genome annotation-orientated databases such as
the Poxviridae database [28] (no longer operating) and the
Virus Pathogen Resource (http://www.viprbrc.org/) [56].
Journal of Immunology Research 9
Figure 3: EPIPOX result page. The figure shows a slice of the output resulting from promiscuous CORE protein peptides binding to the A2
supertype. The output consists of a tabulated list, with information on each of the fields of the search query (columns). From field SOURCE
NAME (1), users can access proteins from the Virus PathogenDatabase (http://www.viprbrc.org/) (1) and by clicking on the epitope sequence,
field SEQ (2), users will get the amino acid sequence of the protein showing the peptide in bold (2).
This later resource contains information on virus sequences,
functional annotations and epitopes derived from IEDB
[24]. However, the Virus Pathogen Resource does not allow
selection of epitopes or antigens by criteria that are relevant
to epitope vaccine design. In fact, EPIPOX is the only
dedicated immunologic resource that has been designed to
facilitate the rational selection of epitopes and antigens for
subunit vaccine design.
4. Conclusions and Future Development
The availability of the VARV genomes enables the use of
predictive tools that reveal entire T-cell epitomes and facil-
itate the development of epitope-based vaccines. However, in
large and complex viruses, such as VARV, the potential T-cell
epitome can be so sizeable that it will challenge experimental
validation. Therefore, in this work we applied a rational
strategy to limit the list of potential T-cell epitopes. First, we
reduced the number of antigens by half by simply selecting
those that are conserved among pathogenic orthopoxviruses
related to VARV. Second, we enriched the antigens with
annotations such as temporal expression and location. Lastly,
we created a resource and de facto analysis pipeline (EPIPOX)
with which to interrogate the resulting T-cell epitome and
enable users to select immunologically relevant subsets of T-
cell epitopes suitable for experimental validation.
We expect that this work and EPIPOXwill be instrumen-
tal in developing safer smallpox vaccines and thereby in pre-
venting zoonosis caused by other orthopoxviruses, including
MPXV, which is also a potential terrorist bioweapon. In the
future, we plan to enhance EPIPOX with validated and/or
experimentally determined epitopes, upgrade protein anno-
tations with functional information, and include additional
features such as TAP transport [57], ERAAP cleavage [58],
and T-cell epitope immunodominance. In sum, we would
expect EPIPOX to establish itself as a facilitating resource of
true utility in inter alia immunoinformatic characterization
of viral genomics and computational reverse vaccinology.
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